Apimeds Pharmaceuticals Financials - Benzinga

Apimeds Pharmaceuticals Us Inc

APUSAMEX

Trade with Public

Trade with Public

$6.83

1.9138.8%

Últ. Act.: Sep 25, 10:23 AM

PRO

¿Por qué se mueve?:Apimeds Pharmaceuticals shares are trading higher after the company announc...

Panorámica general Noticias Previsión de beneficiosFinanzasSentimiento Propiedad Comparar Informe de acciones

Apimeds Pharmaceuticals Financials

Apimeds Pharmaceuticals (APUS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Apimeds Pharmaceuticals Q1 EPS $(2.26) Down From $(0.50) YoY

Apimeds Pharmaceuticals (AMEX:APUS) reported quarterly losses of $(2.26) per share. This is a 352 percent decrease over losses of $(0.50) per share from the same period last year.

Benzinga Newsdesk

PRO
Apimeds Pharmaceuticals Q4 EPS $(0.80) Down From $(0.50) YoY

Apimeds Pharmaceuticals (AMEX:APUS) reported quarterly losses of $(0.80) per share. This is a 60 percent decrease over losses of $(0.50) per share from the same period last year.

Benzinga Newsdesk

PRO
Apimeds Pharmaceuticals Q2 EPS $(0.26) Down From $(0.06) YoY

Apimeds Pharmaceuticals (AMEX:APUS) reported quarterly losses of $(0.26) per share. This is a 333.33 percent decrease over losses of $(0.06) per share from the same period last year.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved